Bio­gen to halt sales and de­vel­op­ment of con­tro­ver­sial Alzheimer's drug Aduhelm

Bio­gen will stop sales and de­vel­op­ment of its con­tro­ver­sial Alzheimer’s drug Aduhelm, walk­ing away from a drug that was ap­proved against out­side ex­perts’ ad­vice, led to con­gres­sion­al in­quiries and faced push­back over its cost and ef­fi­ca­cy.

The com­pa­ny didn’t take the of­fi­cial step of pulling the drug from the mar­ket, but in­stead hand­ed it over to orig­i­nal own­er Neurim­mune. The move es­sen­tial­ly dis­con­tin­ues Aduhelm in its cur­rent form, and Bio­gen took a one-time charge of $60 mil­lion in the fourth quar­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.